SLU-PP-332 dosage chart
5 mg Vial
SLU-PP-332 is dosed at 1.25 mg–2.5 mg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.
- Evidence Base
- Preclinical only—in vivo mouse studies with intraperitoneal dosing (25–50 mg/kg twice daily).
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Murine dose range
- 1250–2500 mcg daily (for a 25 g mouse), administered in two divided doses.
- Easy measuring
- At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: −20 °C (−4 °F); reconstituted: 2–8 °C (35.6–46.4 °F).
Dosing schedule
| Phase | Daily Dose (mcg) | Per-Injection Dose (mcg) | Units per Injection (mL) |
|---|---|---|---|
| Weeks 1–2 | 1250 mcg | 625 mcg | 37.5 units (0.375 mL) |
| Weeks 3–8 | 2500 mcg | 1250 mcg | 75 units (0.75 mL) |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important Notes
- No human data: SLU-PP-332 has not been tested in human subjects; all evidence is from murine models.
- Use new sterile syringes for each administration; dispose in a sharps container.
- Rotate injection sites to reduce local irritation.
- Document administration times, doses, and any observations.
- This compound is for research purposes only—not for human consumption.
How This Works
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), with strongest activity at ERRα. In murine studies, acute administration activated an aerobic-exercise transcriptional program, increased mitochondrial respiration and fatty-acid oxidation in skeletal muscle, and improved endurance capacity and cardiometabolic phenotypes. The compound acts as an “exercise mimetic” by engaging metabolic pathways typically activated during physical training, without requiring the mechanical stress of actual exercise. However, all evidence to date is preclinical—no human trials have been conducted.
Preclinical Observations
- Metabolic effects: Enhanced mitochondrial function, increased fatty-acid oxidation, improved glucose tolerance in diet-induced obese mice.
- Cardiac benefits: Ameliorated heart failure through enhanced cardiac fatty-acid metabolism and mitochondrial function in preclinical models.
- Endurance enhancement: Increased treadmill running capacity and muscle oxidative capacity in mice.
- Renal effects: Reversed mitochondrial dysfunction and inflammation in aging kidney models.
- Human safety unknown: No data on human tolerability, pharmacokinetics, or adverse effects exist.
Research Considerations
Contextual factors for preclinical research.
- SLU-PP-332 was studied alongside exercise training in some murine models, suggesting potential synergistic effects.
- Diet composition (standard chow vs. high-fat diet) influenced metabolic outcomes in published studies.
- Environmental controls (temperature, housing conditions) should be standardized in research protocols.
- Compound stability and handling procedures are critical for reproducible results.
Administration Technique
General subcutaneous guidance (note: published studies used intraperitoneal route).
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- For subcutaneous administration: pinch a skinfold; insert needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Note: Published murine studies used intraperitoneal administration; subcutaneous route is not validated for this compound.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. SLU-PP-332 is a preclinical research compound with no human safety or efficacy data. This information is for research and educational purposes only—not for human consumption.
SLU-PP-332 dosage FAQs
How much bacteriostatic water do you use to reconstitute SLU-PP-332?
Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration. for a 5 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What is a typical SLU-PP-332 dose?
Murine dose range: 1250–2500 mcg daily (for a 25 g mouse), administered in two divided doses.. Figures are research reference values only.
What does the SLU-PP-332 dosing schedule look like?
Weeks 1–2 — 1250 mcg — 625 mcg — 37.5 units (0.375 mL); Weeks 3–8 — 2500 mcg — 1250 mcg — 75 units (0.75 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for SLU-PP-332?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted SLU-PP-332 be stored?
Storage: Lyophilized: −20 °C (−4 °F); reconstituted: 2–8 °C (35.6–46.4 °F)..
How many insulin syringe units equal a SLU-PP-332 dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is SLU-PP-332 approved for human use?
No. SLU-PP-332 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.